Articles tagged "Malignancy"

2016 American Transplant Congress
Beyond the Bones – The Association Between Vitamin D, Graft Outcomes and Vascular Disease.
A. Cherukuri,¹ S. Balasubramanian,² R. Molyneux,² R. Baker.
¹UPMC, Pittsburgh; ²University of Leeds, Leeds, United Kingdom.
Background: Vitamin D deficiency in KTRs is an emerging theme. The purported associations between Vitamin D deficiency and various metabolic, cardiovascular and non-metabolic adverse events…
2016 American Transplant Congress
Long-Term Outcomes After Pediatric Liver Transplantation for Malignant Liver Tumors: Effects of Era and Age.
R. Patel,¹ I. Feurer,¹ S. Karp,¹ L. Gillis,¹ H. Katzenstein,¹ H. Lovvorn III,¹ J. Pietsch,¹ D. Chung, G. Tiao,² D. Hanto.¹
¹Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN; ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Background: Hepatoblastoma (HB), hepatocellular carcinoma (HCC), along with hemangioendothelioma, hemangiosarcoma, and angiosarcoma (HHA) are rare tumors in children that are treated with orthotopic liver transplantation…
2016 American Transplant Congress
Safety of a Short (One-Year) Waiting Time in Kidney Transplant Candidates Treated for Cancer.
D. Dahle,¹ T. Grotmol,² T. Leivestad,³ A. Hartmann,¹ G. Mjøen,¹ H. Pihlstrøm,¹ H. Næss,¹ H. Holdaas.¹
¹Department of Transplant Medicine, Oslo University Hospital, Oslo, Norway; ²The Cancer Registry of Norway, Oslo, Norway; ³Norwegian Renal Registry, Oslo University Hospital, Oslo, Norway.
In Norway, a one-year waiting time free of cancer recurrence is required before kidney transplantation. To provide an updated, large-scale assessment of this practice, the…
2016 American Transplant Congress
Integrative, Multi-Cohort Analysis of Epstein-Barr Virus (EBV)-Positive and Negative Tumor Samples to Identify Gene-Signatures Associated with EBV Oncogenesis.
E. Maloney, E. Bongen, F. Vallania, N. Kotecha, P. Khatri, O. Martinez.
Stanford School of Medicine, Stanford, CA.
EBV is linked to a variety of lymphoid and epithelial malignancies. In transplant recipients EBV is associated with the development of B cell lymphomas in…
2015 American Transplant Congress
Donor-Derived Tumor Transmission Events. A Summary of 2008-2013 Data from the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC)
M. Nalesnik,¹ S. Taranto,² S. Covington,² E. Blumberg,¹ M. Green,¹ T. Gross,¹ M. Klassen-Fischer,¹ M. Pavlakis,¹ C. Wolfe,¹ D. Kaul.¹
¹OPTN Disease Transmission Advisory Committee (DTAC), Richmond, VA; ²United Network for Organ Sharing, Richmond, VA.
Purpose: Transmission of donor malignancy via transplantation is an uncommon but significant occurrence. The OPTN Disease Transmission Advisory Committee (DTAC) has monitored such complications since…
2015 American Transplant Congress
Deficiency of Naturally Occurring Anti-Angiogenic Antibodies Associate With the Development of Metastatic Cancer Post Renal Transplantation and Patient Death
R. Carroll,¹ A. Phillippe,² R. Catar,² H. Heidecke,² D. Dragun.²
¹Central Northern Adelaide Renal and Transplantation Service, Royal Adelaide Hospital, Adelaide, SA, Australia; ²Centre for Cardiovascular Research, Charite Hospital, Berlin, Germany.
We assessed the presence of naturally occurring blocking antibodies to mediators of vascularisation and metastasis in Kidney Transplant Recipients (KTR) with metastatic cancer (n=11), non…
2015 American Transplant Congress
Everolimus-Based Immunosuppression Is Associated With a Reduced Risk of New-Onset Malignancies After Liver Transplantation
P. De Simone,¹ P. Carrai,¹ L. Coletti,¹ D. Ghinolfi,¹ D. Campani,² F. Filipponi.¹
¹Hepatobiliary Surgery and Liver Transplantation, University of Pisa Medical School Hospital, Pisa, Italy; ²Pathology, University of Pisa Medical School Hospital, Pisa, Italy.
Background and aim: The inhibitor of the mammalian target of rapamycin (mTOR) everolimus (EVR) has shown anti-proliferative effects in experimental and clinical models. We investigated…
2015 American Transplant Congress
Clinical Outcomes of Kidney Transplan Recipients After Sirolimus Or Everolimus Conversion. Experience in a Single Center
L. Mesa, E. Manzi, M. Valderrama, J. Posada, J. Schweineberg, C. Duran, G. Echeverri, J. Villegas, O. Serrano, L. Caicedo.
Transplant Unit, Fundación Valle del Lili, Cali, Colombia.
Introduction. The use of m_TOR inhibitors sirolimus (SRL) and everolimus (EVL), in kidney transplant recipients (KTR) is an alternative immunosuppressive therapy to reduce or withdrawal…
2015 American Transplant Congress
Allo-Stimulated Interferon-γ Release and Natural Killer Cell Function Defines and Risk Stratifies Cancer Development in Kidney Transplant Recipients Who Have Cancer Post-transplantation
C. Hope,^1,2 A. Fuss,^1,2 W. Hanf,¹ P. Coates,^1,2 P. Heeger,³ R. Carroll.^1,2
¹The Centre for Clinical and Experimental Transplantation (CCET), Central Northern Adelaide Renal and Transplantation Services (CNARTS), Adelaide, South Australia, Australia; ²Medicine, The University of Adelaide, Adelaide, South Australia, Australia; ³Icahn School of Medicine, The Recanati-Miller Transplant Institute, New York City, NY.
Reducing immunosuppression is efficacious in primary prevention of cancer in Kidney Transplant Recipients (KTR) but can precipitate graft rejection. Conventional immunosuppressive drug monitoring fails to…
2015 American Transplant Congress
Early Detection of HCC Mutations in Indeterminate Lesions Using Liquid Biopsies
Y. Lin,¹ K. Cavaness,² Z. Zhang,¹ S. Lin,³ K. Korenblat,¹ G. Klintmalm,² W. Chapman.¹
¹Washington University, St. Louis, MO; ²Baylor University, Dallas, TX; ³Stanford University, Palo Alto, CA.
Background Recent sequencing efforts have characterized the mutation profile of hepatocellular carcinoma (HCC); however, the relevance to clinical decision-making has been limited by the infrequency…